Moderna submits preliminary data to FDA for Covid-19 booster shot

Moderna has commenced its submission to the US Food and Drug Administration (FDA) for the assessment of a booster shot of its Covid-19 vaccine, mRNA-1273, at the 50µg dose level. The company plans to make similar submissions to the European Medicines Agency (EMA), as well as other global regulatory agencies soon. In December last year, the FDA authorised the emergency use of this messenger ribonucleic acid (mRNA) vaccine for people aged 18 years or above.